Comparison of the Serum Lipid Concentratıons Between Women With Pcos and Healthy Women- a Retrospective Study

Yıl 2016, Cilt: 30 Sayı: 2, 71 - 77, 21.10.2016

Özgür Yılmaz , Halil Gürsoy Pala Tuncay Küme , Burcu Artunç Ülkümen

Öz

Objective: Hyperlipidemia is
the one of the most common metabolic disorders in PCOS. Therefore in this study
we aim to evaluate lipid concentrations in women with or without PCOS in our
population.

Methods: Fifty five women
with PCOS and fifty five age and body mass index (BMI) matched healthy women
were retrospectively assessed. Fasting serum high-density lipoprotein(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
and total cholesterol, triglyceride, glucose and insulin concentrations were
evaluated.

Results: There were no
significant differences between two groups according to serum fasting total
cholesterol, HDL cholesterol, LDL cholesterol, glucose and insulin
concentrations (p>0.05). Serum
triglycerides (121.13±42.633 mg/dL versus 94.444±41.809 mg/dL; p=0.004) and total tetosterone
concencentrations (46.422±18.551ng/mL versus 36.546±14.365ng/mL; p=0.006) were significantly higher in
women with PCOS. According to linear regression analysis, only triglyceride
levels were associated with PCOS (β=0.262; p=0.016).

Discussion and
conclusion: Although, as a metabolic disorder, hyperlipidemia is an expected finding
in PCOS; there are conflicting results depending on the evaluated population.
Therefore advanced longitudinal studies are necessary to explain the relationship
between PCOS and lipid levels in our country.

Anahtar Kelimeler

HDL cholesterol, LDL cholesterol, hyperlipidemia, Polycystic ovary syndrome

Polikistik Over Sendromlu Kadınların Serum Lipid Konsantrasyonlarının Sağlıklı Kadınlar ile Kıyaslanması- Geriye Yönelik (Retrospektif) İnceleme

Öz

Bu nedenle biz bu çalışmada PKOS’lu ve ek sağlık
problemi olmayan kadınlar arasındaki lipid parametrelerini kıyaslayarak
incelediğimiz populasyonda hangi parametreler arasında farklılıklar olduğunu ve
bu farklılıkların düzeyini incelemeyi amaçladık.

Yöntem
ve gereçler: 45 PKOS’lu ve 45 sağlıklı kadın yaş ve vücut kitle
indeksi (VKİ) kıyaslamalı olarak retrospektif olarak incelendi. Serum açlık
total kolesterol, yüksek dansiteli lipoprotein (HDL) kolesterol, düşük
dansiteli lipoprotein (LDL) kolesterol, trigliserid, glukoz ve insülin
düzeyleri değerlendirildi.

Bulgular:
Gruplar arasında serum açlık glukoz, total kolesterol, HDL kolesterol, LDL
kolesterol ve insülin konsantrasyonlari arasında anlamlı fark bulunmadı (p>0.05). Serum trigliserid (121,13±42,633
mg/dL ve 94,444±41,809 mg/dL; p=0,004)
ve serum total testosteron konsantrasyonu (46,422±18,551ng/mL ve 36,546±14,365ng/mL;
p=0,006) ise PKOS'lularda anlamlı
olarak daha yüksek saptandı. Lineer regresyon analizinin sonuçlarına göre
sadece trigliserid düzeyleri PKOS ile anlamlı birliktelik gösteriyordu (β=0,262;
p=0,016).

Tartışma
ve sonuç: Bir metabolik bozukluk olarak PKOS’da hiperlipidemi
beklenen bir bulgu olsa da; incelenen populasyonlara bağlı olarak farklı
sonuçlar mevcuttur. Bundan dolayı PKOS’lu kadınlara uygulanacak tedavilerin
uygun planlanması amacı ile ülkemize ait geniş sayıda olguyu içeren longitudinal
çalışmalardan elde edilecek verilere ihtiyaç vardır.

Anahtar Kelimeler

HDL kolesterol, LDL kolesterol, Hiperlipidemi, Polikistik over sendromu, Trigliserid

Kaynakça

• Referans1 Mohamed-Hussein ZA, Harun S. Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data.Theor Biol Med Model 2009;1;6:18. doi: 10.1186/1742-4682-6-18.
• Referans2 Cheang KI, Huszar JM, Best AM, Sharma S, Essah PA, Nestler JE. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diab Vasc Dis Res 2009;6:110-119.
• Referans3 Randeva HS, Tan BK, Weickert MO, Lois K, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812-841.
• Referans4 Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010;2010:758656.
• Referans5 Aye MM, Kilpatrick ES, Aburima A, Wraith KS, Magwenzi S, Spurgeon B, Rigby AS, Sandeman D, Naseem KM, Atkin SL. Acute hypertriglyceridemia induces platelet hyperactivity that is not attenuated by insulin in polycystic ovary syndrome. J Am Heart Assoc 2014;3:e000706. doi: 10.1161/JAHA.113.000706.
• Referans6 Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:48–53.
• Referans7 Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929–1935.
• Referans8 Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812-841.
• Referans9 Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008;4:215–222.
• Referans10 Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35–43.
• Referans11 Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism 2009;58:714–721.
• Referans12 Kim JJ, Chae SJ, Choi YM, Hwang KR, Song SH, Yoon SH, Kim SM, Ku SY, Kim SH, Kim JG, Moon SY. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Hum Reprod 2013;28:1354-1360.
• Referans13 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.
• Referans14 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
• Referans15 Hoffman LK, Ehrmann DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2008;4:215–222.
• Referans16 Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37:119-125.
• Referans17 Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S, Aliasgharzadeh A, Aliashrafi S, Rezayi N, Mehrzad-Sadaghiani M. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome. J Health Popul Nutr 2015;33:157-167.
• Referans18 Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994;41:463-471.
• Referans19 Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R, Bush A, Richmond W, Johnston DG, Franks S. Dyslipidaemia is associated with insulin resistance in women with polycystic ovarie. Clin Endocrinol (Oxf) 1996;44:277-284.
• Referans20 Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012;18(6):618-37.
• Referans21 Legro RS. Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28(1):99-109.
• Referans22 Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470–476. Referans23 Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, Carmina E. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. Int J Clin Pract 2009;63:56–62.
• Referans24 Kim JJ, Chae SJ, Choi YM, Hwang KR, Song SH, Yoon SH, Kim SM, Ku SY, Kim SH, Kim JG, Moon SY. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome. Hum Reprod 2013;28:1354-1360.
• Referans25 Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, Mehta NN, Dokras A. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab 2014;99:E841-847.
• Referans26 Benítez R, Sir-Petermann T, Palomino A, Angel B, Maliqueo M, Perez F, Calvilla´n M. Prevalence of metabolic disorders among family members of patients with polycystic ovary syndrome. Rev Med Chil 2001;129:707–712.
• Referans27 Joharatnam J, Barber TM, Webber L, Conway GS, McCarthy MI, Franks S. Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters. Clin Endocrinol (Oxf) 2011;74:714–719.
• Referans28 Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK,Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336–1345.